EE525 Cost Effectiveness of the Chimeric Antigen Receptor (CAR) T Cell Treatment Lisocabtagene Maraleucel (Liso-Cel) As Second-Line (2L) Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) in Switzerland
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.790
https://www.valueinhealthjournal.com/article/S1098-3015(23)03920-7/fulltext
Title :
EE525 Cost Effectiveness of the Chimeric Antigen Receptor (CAR) T Cell Treatment Lisocabtagene Maraleucel (Liso-Cel) As Second-Line (2L) Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) in Switzerland
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03920-7&doi=10.1016/j.jval.2023.09.790
First page :
Section Title :
Open access? :
No
Section Order :
10275